Thyroid Eye Disease Study (TED)

Thyroid Eye Disease Study (TED)

The 421-01-02 study is a clinical research study that will assess the safety and effectiveness of an investigational drug (lonigutamab) as a potential new treatment for patients with active thyroid eye disease (TED). Lonigutamab is a new drug which may help relieve the symptoms of thyroid eye disease.

Principal Investigator: Dr Jean-Louis DeSousa

ClinicalTrials.gov Identifier: NCT05683496

To enquire further about this study, please contact the Clinical Trials office on (08) 9381 0750, or email clinicalresearch@lei.org.au.

Need any help?

If you would like to know more about us, or want to make an appointment, please don’t hesitate to get in touch.

Request an appointment